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Background: In nephrotic syndrome, the combination of furosemide and albumin infusion is 
a standard regimen to treat systemic edema. The efficacy of synthetic human atrial natriuretic 
peptide (hANP) for nephrotic syndrome to ameliorate the systemic edema and retain renal 
functions has not been fully demonstrated.
Trial design: We conducted a prospective, randomized, controlled, open-label clinical trial. 
Patients were randomly assigned by a stratified biased coin design.
Methods: A total of 12 patients with nephrotic syndrome between the ages of 20 to 79 years 
were enrolled and randomly assigned to either the conventional (CON) group treated with 
furosemide and albumin, and hANP group, in which carperitide was administered in addition to 
the conventional therapies. The primary end points were: (1) the differences in serum creatinine 
levels, and (2) the reduction of total dosage of furosemide and albumin by the treatments 
of hANP. Secondary end points were body weight, systolic blood pressure, heart rate, serum 
protein, albumin, and urinary protein excretion.
Results: A total of 13 patients were enrolled, and one patient was excluded due to severe 
pneumonia. In both hANP (n = 7) and CON (n = 5) groups, body weight was reduced after 
2-week treatments. Serum creatinine levels at follow-up significantly increased compared with 
baseline. The increase in serum creatinine levels (∆ serum creatinine) was smaller in the hANP 
group compared with the CON group (P = 0.31). The serum uric acid, serum urea nitrogen, and 
urinary protein excretion were reduced in the hANP group, and increased in the CON group, 
though these differences were not statistically significant. The usage of hANP significantly 
reduced the total dosage of furosemide (P , 0.05) during the treatment periods. No adverse 
effects were observed.
Conclusions: The concomitant use of synthetic hANP with conventional therapies is beneficial 
for reducing the dosage of loop diuretics, and the elevation of serum creatinine and uric acid 
may be avoided.
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Introduction
Atrial natriuretic peptide (ANP) was discovered in 1992, and it was found that the 
exogenous infusion of ANP decreases systemic blood pressure, while increasing 
glomerular filtration rate (GFR), filtration fraction, and salt and water excretion.1 
Synthetic human atrial natriuretic peptide (hANP), carperitide, has been used for the 
treatment of heart failure in Japan. The administration of hANP exerted beneficial 
effects in experimental and clinical acute renal failure.2,3 Although brain natriuretic 
peptide (BNP) demonstrated qualitatively similar physiological effects with potent 
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blood pressure-lowering effects, the effects of BNP on renal 
function in patients with heart failure remained controversial. 
One study demonstrated that low-dose synthetic human BNP, 
nesiritide, improves renal function in heart failure patients 
following myocardial infarction,4 whereas another reported 
that nesiritide does not improve renal function in patients with 
chronic heart failure and worsening serum creatinine.5
In nephrotic syndrome, the combination of furosemide 
and albumin infusion is commonly used to relieve systemic 
edema and the symptoms of congestive heart failure. We 
often encounter the cases where the administration of 
furosemide worsens renal function and induces abnormalities 
of electrolytes. The previous case report demonstrated the 
efficacy of hANP in ameliorating systemic edema while 
maintaining renal function in a patient with nephrotic 
syndrome.6 This finding prompted us to examine the 
effectiveness of hANP on systemic edema in nephrotic 
syndrome and compare the adverse effects with conventional 
therapy.
Subjects and methods
Study design, setting, and participants
We conducted the prospective, randomized, controlled, 
open-label clinical trial at Okayama University Hospital. 
Patients were eligible and included in the study if they 
presented with nephrotic syndrome complicated with 
congestive heart failure, massive pleural effusion, ascites, 
and peripheral edema. The diagnosis of nephrotic syndrome 
was based on urinary protein excretion of more than 
3.5 g/day, serum total protein level less than 60 g/L, or 
serum albumin level less than 30 g/L. Subjects with a serum 
creatinine level of more than 305 µmol/L, with systemic 
hypotension (systolic blood pressure , 100 mmHg), with 
cardiogenic shock, and with ischemic heart disease within 
one month before their entry were excluded. The diagnosis of 
diabetic nephropathy among subjects was made on the basis 
of their having a history of diabetes for at least more than 
10 years, while also presenting with diabetic retinopathy. 
The use of antihypertensive agents such as angiotensin II 
receptor blockers, angiotensin converting enzyme inhibitors, 
β or α blockers, or aldosterone blockers was permitted, 
and could be administered concurrently for maintaining 
participants’ blood pressure under 125/75 mmHg. The study 
was conducted in accordance with the ethical principles of 
the Declaration of Helsinki and approved by the Institutional 
Review Board of Okayama University Hospital (#050305). 
All patients provided written informed consent to participate 
in this study.
Study protocol and outcome measures
A total of 13 patients ranging in age from 20 to 79 years old 
were enrolled in the study between January 2007 and October 
2010. Participants were randomly assigned by way of stratified 
biased coin design, to either the synthetic human atrial natriuretic 
peptide (hANP, n = 7) or the conventional treatment (CON, 
n = 6) groups. Participants were treated for 2 weeks (Table 1). 
Incidentally, more diabetic patients were assigned to the hANP 
group. One patient with diabetic nephropathy in the CON group 
was excluded due to the onset of severe pneumonia during the 
intervention. In the CON group, furosemide at maximum dosage 
of 200 mg/day was orally or intravenously administered during 
the course of the study, and daily doses were adjusted to maintain 
participants’ urine volume more than 2000 mL/day. When serum 
albumin level was less than 20 g/L, 50 mL of 25% albumin 
per week was supplemented. In the hANP group, synthetic 
hANP, carperitide, was continuously administered concurrently 
with the conventional therapies. The starting dose of synthetic 
hANP was 0.01 µg/kg/min and the infusion rate was gradually 
increased up to 0.2 µg/kg/min. To maintain participants’ 
blood pressure at more than 100 mmHg, the daily dosage 
of antihypertensive agents was reduced or discontinued.
The primary end points of this study were: (1) the 
preservation of renal function evaluated by the changes in 
serum creatinine level; and (2) the reduction of total dosage 
of furosemide and albumin by the treatments of hANP, (ie, 
carperitide). Secondary end points were participants’ body 
weight, systolic blood pressure, heart rate, serum protein, 
albumin, and urinary protein excretion. In a preliminary 
evaluation, the standard deviation of the total dosage of 
Table 1 Comparison of clinical characteristics of synthetic human 
atrial  natriuretic  peptide  treatment  (hANP)  and  conventional 
treatment (CON) groups at baseline
hANP  
(n = 7)
CON  
(n = 5)
P values
Gender (female:male) 3:4 2:3
Age (year)   59.4 ± 5.3   67.0 ± 4.0 ns
Systolic BP (mmHg) 147.9 ± 12.0 147.0 ± 12.6 ns
Diastolic BP (mmHg)   78.0 ± 5.7   82.0 ± 6.1 ns
Heart rate (beats/min)   85.1 ± 6.3   74.8 ± 3.9 ns
Serum total protein (g/L)   49.0 ± 4.0   53.0 ± 4.0 ns
Serum albumin (g/L)    23 ± 2.0   23.0 ± 3.0 ns
Urinary protein excretion  
(g/day)
  6.3 ± 1.9   5.9 ± 1.3 ns
Underlying diseases 
Diabetic nephropathy 
Primary glomerulonephritis
 
n = 6 
n = 1
 
n = 2 
n = 3
Abbreviations:  hANP,  synthetic  human  atrial  natriuretic  peptide  treatment;   
CON, conventional treatment; BP, blood pressure; ns, not significant.
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furosemide in the patients with nephrotic syndrome was 
normally distributed with a standard deviation of 250 mg. 
If the true difference in means between the experimental 
and control conditions is 500 mg, we will need to study five 
experimental subjects and five control subjects to be able to 
reject the null hypothesis that the population means of the 
experimental and control groups are equal with probability 
(power) of 0.8. The Type I error probability associated with 
testing this null hypothesis is 0.05.
Statistical analysis
All data are shown as the means ± SEM (standard error of the 
mean) unless otherwise noted. Differences between paired 
variables were analyzed by nonparametric tests, ie, Wilcoxon 
and Mann–Whitney tests. Statistical analysis was conducted 
with PASW Statistics 18 (SPSS Inc, Chicago, IL). P values 
of less than 0.05 were considered statistically significant.
Results
A total of 13 patients were randomly assigned to the hANP 
(n = 7) and CON (n = 6) groups and treated throughout 
the course of the study. One patient in the CON group 
developed a severe infection and was excluded from the 
study (Figure 1). During the study period, any adverse 
effects, such as hypotension and deterioration of renal 
function, were not observed. At baseline, there were no 
significant differences in various clinical parameters such 
as blood pressure, serum total protein, and urinary protein 
excretion (Table 1). However, it is important to note that 
more patients with diabetic nephropathy were assigned to the 
hANP group (n = 6) than to the CON group (n = 2). Across 
both groups, body weight was reduced among all participants 
after a 2-week treatment regimen, although this change was 
not statistically significant (p=0.063 in hANP and p=0.223 
in CON groups). In both hANP and CON groups, serum 
creatinine levels at follow-up significantly increased when 
compared with baseline (Table 2).
The increase in serum creatinine levels (∆ serum creatinine) 
tended to be smaller in the hANP group (3.95 µmol/L; 
range 0.9–18.6) compared with CON group (11.5 µmol/L; 
range 0–38.9) (P = 0.31) (Figure 2A). The serum uric acid, 
serum urea nitrogen, and urinary protein excretion were 
reduced in hANP group, while the CON group exhibited an 
increase in these levels; however, these differences were not 
statistically significant (Figure 2B–D). The administration of 
hANP significantly reduced the total dosage of furosemide 
(220 mg [range 0–1560] vs 800 mg [range 400–1720]; 
P , 0.05) (Figure 2E). The usage of hANP also reduced 
the total volume of infused albumin, but this reduction 
was also not statistically significant (0 g [range 0–225] vs 
0 g [range 0–400]; P = 0.80) (Figure 2F).
Discussion
The majority of patients with nephrotic syndrome 
experience severe edema due to primary renal sodium 
retention where the tubular sodium reabsorption, mainly 
in the distal tubule, is enhanced and predominates over 
the mechanisms involved in regulating extrarenal volume 
mechanisms.7 In addition to the inability of the renal distal 
tubule to excrete salt, vascular hyperpermeability also plays 
a role in the pathophysiology of nephrotic edema.8 Two 
extremes of   volume status, hypervolemia and hypovolemia, 
may be found in patients with nephrotic syndrome; however, 
hypovolemia is predominately due to consequences of 
conventional therapies.9 Renal sodium retention should 
normally be counterbalanced by enhanced secretion of 
sodium in the inner medullary collecting duct, primarily 
mediated by the release of ANP. This regulatory pathway 
is curtailed in patients and rats with nephrotic syndrome by 
enhanced catabolism of cyclic GMP following phosphodi-
esterase activation,10 or by the impairment of subsequent 
ANP signaling pathways such as cyclic GMP-dependent 
protein kinases.11 The line of conceptual changes of 
pathogenesis associated with nephrotic syndrome prompted 
us to assume that the administration of hANP for nephrotic 
syndrome is beneficial for increasing sodium excretion and 
relieving generalized edema.
Assessed for eligibility(n = 13)
Randomized (n = 13)
Allocated to hANP group
(n = 7)
Allocated to CON group
(n = 6)
Alloca￿on
Follow-up
Discon￿nued therapy
(n = 0)
Discon￿nued therapy:
because of severe
infec￿on (n = 1)
Analyzed (n = 7)
Excluded from analysis (n = 0)
Analyzed (n = 5)
Excluded from analysis (n = 0)
Analysis
Enrollment
Figure 1 CONSORT (Consolidated Standards of Reporting Trials) diagram for the 
current study.
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In the current study, synthetic hANP relieved systemic 
edema in patients with nephrotic syndrome without any of 
the possible adverse effects that may have impacted renal 
function, including elevation of serum creatinine, urea 
nitrogen, and uric acid when compared with conventional 
therapies (ie, furosemide and albumin). ANP was reported 
to play an important role in albumin-induced natriuresis 
in patients with nephritic syndrome;12 the use of hANP in 
  conjunction with furosemide and albumin has synergistic 
effects on the sodium excretion. We can speculate that 
the excessive reduction of blood pressure associated with 
the administration of synthetic ANP or BNP may lead to 
Table 2 Clinical parameters at baseline and follow-up in synthetic human atrial natriuretic peptide treatment (hANP) and conventional 
treatment (CON) groups
hANP CON
Baseline 2 weeks P Baseline 2 weeks P
Systolic BP (mmHg) 147.9 ± 12.0 131.7 ± 5.9 ns 147.0 ± 12.6 131.4 ± 11.4 ns
Diastolic BP (mmHg)   78.0 ± 5.7   71.9 ± 7.9 ns   82.0 ± 6.1   75.4 ± 11.5 ns
Heart rate (beats/min)   85.1 ± 6.3   77.6 ± 3.4 ns   74.8 ± 3.9   78.5 ± 3.1 ns
Body weight (kg)   61.0 ± 3.5   58.6 ± 3.8 ns   65.2 ± 18.7   61.6 ± 18.7 ns
Serum sodium (mmol/L) 136.0 ± 2.0 139.0 ± 1.0 ns 141.0 ± 2.0 142.0 ± 1.0 ns
Serum potassium (mmol/L)     4.4 ± 0.1   4.37 ± 0.3 ns   4.50 ± 0.2   3.92 ± 0.2 ns
Serum total protein (g/L)   49.0 ± 2.0   51.0 ± 8.0 ns   53.0 ± 4.0   52.0 ± 11.0 ns
Serum albumin (g/L)   23.0 ± 2.0   25.0 ± 2.0 ns   23.0 ± 3.0   26.0 ± 3.0 ns
Serum creatinine (µmol/L) 176.8 ± 79.6 185.6 ± 88.4 P , 0.05 221.0 ± 88.4 238.7 ± 114.9 P , 0.05
Serum uric acid (µmol/dL) 399.0 ± 107.0 387.0 ± 83.0 ns 494.0 ± 48.0 595.0 ± 48.0 ns
Serum urea nitrogen (mmol/L)   15.5 ± 21.8     9.1 ± 7.2 ns     9.9 ± 5.7   13.3 ± 2.9 ns
Urinary protein excretion (g/day)     6.8 ± 5.4     5.6 ± 3.2 ns     5.9 ± 1.3     6.6 ± 2.3 ns
Abbreviations: hANP, synthetic human atrial natriuretic peptide treatment; CON, conventional treatment; BP, blood pressure; ns, not significant.
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Figure 2 Comparison of changes of clinical parameters and total dose of furosemide and albumin in synthetic human atrial natriuretic peptide treatment (hANP) and 
conventional treatment (CON) groups. Note: *P < 0.05.
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the deterioration of renal function. In previous reports, the 
low dose of nesiritide 0.0075 µg/kg/min improved renal 
function,13 whereas the intermediate dose 0.01 µg/kg/min 
had a converse effect on renal function.5,14 In our study, we 
maintained participants’ systolic blood pressure at more 
than 100 mmHg by adjusting the dosage of carperitide 
from 0.01 to 0.20 µg/kg/min. BNP exerted more potent 
hypotensive actions when compared with ANP, and the 
study also suggested that the deterioration of renal func-
tion may be due to the excessive reduction of systemic 
blood pressure.
ANP has been classified as a renoprotective peptide, 
since it also inhibits the renin–angiotensin system (RAS). By 
inhibiting RAS, ANP may cause vasodilatation, suppression 
of sympathetic tone, and cell growth arrest. Through these 
biological mechanisms, the administration of hANP exerted 
beneficial effects on experimental and clinical acute renal 
failure.2,3 Contrary to these reports, ANP was also reported 
to increase urinary albumin excretion in normoalbuminuric 
patients with type 1 and type 2 diabetes.15,16 In patients with 
nephrotic syndrome, plasma ANP levels were significantly 
higher, and the elevated ANP enhanced urinary protein 
excretion. This is not due to modulation of GFR or 
filtration fraction, but rather is most probably attributable 
to an increase in glomerular permeability.17 Thus, we 
were concerned that carperitide might increase urinary 
protein excretion in the patients with nephrotic syndrome; 
however, the administration of carperitide did not increase 
urinary protein excretion levels. In the current study, three 
of seven patients in the hANP group were introduced into 
hemodialysis therapies during a 4-year follow-up period, 
whereas two of five patients in the CON group were 
introduced into hemodialysis.
There were some limitations in the current study. First, 
this study was an open-label trial, thus it is possible that the 
results may have been influenced by unconscious bias of the 
investigators, who were unblinded and aware of who received 
which intervention. Second, the randomization protocol 
did not completely balance the ratio between diabetic and 
nondiabetic kidney diseases, which may affect the outcome 
of the study. Third, the current investigation was a pilot 
study that aimed to demonstrate the clinical usefulness of 
hANP in nephrotic syndrome, and the sample population 
may have been too small to reach statistically significant 
effects. Most notably, a larger sample population may have 
yielded significant results across the various primary and 
secondary end points, with the exception of the reduction in 
dosage of furosemide. Another criticism is that the cost of 
synthetic hANP is much higher than furosemide; however, 
the reduction of albumin infusion may compensate for the 
medical cost. At this stage, we conclude that concomitant use 
of synthetic hANP with conventional therapy is beneficial 
for reducing the dosage of loop diuretics. Future research is 
required to demonstrate that the concomitant use of synthetic 
hANP with conventional therapy is beneficial for improving 
intractable generalized edema among patients with nephrotic 
syndrome, while curtailing such adverse effects as elevation 
in serum creatinine and uric acid levels.
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